Xenetic Biosciences, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report. Comparisons below are to fiscal 2021.
Business context
Xenetic is a clinical-stage biopharmaceutical company with no approved products. Its main strategic focus shifted in 2022 to the DNase oncology platform, licensed in April, intended to target neutrophil extracellular traps (NETs) and potentially improve existing cancer treatments. The company is advancing systemic DNase for pancreatic and other advanced solid tumors, with a first-in-human study start targeted for 2024–2025. DNase-armored CAR T is in early preclinical development. XCART development was suspended as resources were redirected; PolyXen is not being actively developed internally, though it generates royalties through a partner.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Revenue, entirely royalties | $1.707 million | $1.161 million | Up 47.1% |
| Research and development expense | $4.771 million | $3.163 million | Up 50.8% |
| General and administrative expense | $3.654 million | $3.744 million | Down 2.4% |
| Operating loss | $6.718 million | $5.747 million | Loss increased $0.971 million |
| Net loss | $6.552 million | $5.645 million | Loss increased $0.907 million |
| Net loss per share, basic and diluted | $0.46 | $0.55 | Loss per share narrowed |
| Cash used in operating activities | $4.647 million | $4.738 million | Use decreased $0.091 million |
Royalty revenue came from Takeda’s sublicense of PolyXen technology; no product sales were reported. Takeda royalties were approximately $1.7 million in 2022 versus $1.2 million in 2021. The filing does not report a meaningful gross margin; the business remains loss-making and dependent on partner royalties and financing.
Cash was $13.097 million at year-end, down from $18.244 million. Working capital was $12.6 million versus $17.3 million. Total current liabilities were $1.073 million; the balance sheet reports no debt. Investing cash use was $0.5 million for the DNase license, and there were no financing cash flows in 2022. Total assets were $14.720 million, stockholders’ equity was $13.647 million, and accumulated deficit was $189.1 million.
R&D included $1.794 million of acquired in-process R&D expense related to the DNase licenses. Excluding that charge, R&D expense was approximately $3.0 million, down 5.9% year over year. The increase in reported net loss reflects higher operating costs, partly offset by increased royalties and interest income. Weighted-average common shares rose to 14.224 million from 10.279 million.
Material developments, outlook and risks
- DNase licenses: The CLS sublicense and license agreements included $0.5 million in cash consideration and common shares; the company also issued 850,000 shares for a related patent assignment. The agreements provide for potential cash milestones of up to $13 million under each agreement, additional regulatory-milestone shares under the sublicense, royalties on licensed-product sales, and sharing of certain sublicense proceeds. No contingent milestones were recognized at year-end.
- Development spending: Catalent’s DNase manufacturing work was estimated to cost up to approximately $5 million, with completion targeted for the first half of 2024; the work statement is terminable by Xenetic on 30 days’ notice. In March 2023, Xenetic separately agreed to fund up to $938,000 of Scripps Research work on DNase preclinical development.
- Collaborations: Volition agreed to fund an exploratory collaboration combining its Nu.Q technology with Xenetic’s DNase-armored CAR T platform; proceeds from any resulting commercialization or licensing are to be shared. The company does not anticipate significant near-term milestone or royalty receipts beyond Takeda royalties and possible partner royalties.
- Funding and going concern: Management disclosed that recurring losses raise substantial doubt about the company’s ability to continue as a going concern. Management nevertheless believes existing resources can fund operations for at least 12 months from issuance of the financial statements; longer-term development will require additional capital. No committed external funding source was reported.
- Listing: Nasdaq granted an extension through May 29, 2023 to regain the $1 minimum bid-price requirement; the company stated it might use a reverse stock split. Failure to regain compliance could result in delisting and constrain financing.
- Bank exposure after year-end: Substantially all cash was held at Silicon Valley Bank, which was closed in March 2023. Xenetic reported full access to its funds by March 13, 2023 and did not anticipate losses, but the filing identifies uninsured-deposit and broader banking-system risks.
- Other key risks: Success is highly dependent on early-stage DNase development, clinical and regulatory outcomes, manufacturing and research partners, and future financing. The company has four full-time employees, no in-house manufacturing or commercial capabilities, and faces potential dilution from equity financing and outstanding securities. The filing also identifies potential impairment risk for acquired R&D assets.
The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal control effectiveness because Xenetic is a non-accelerated filer.
Important facts for investors to verify
- Whether cash and the operating plan remain sufficient, and when additional financing may be needed.
- Progress toward the targeted 2024–2025 first-in-human systemic DNase study, including preclinical results, regulatory interactions, and manufacturing milestones.
- The timing and expected cash impact of Catalent work and the Scripps Research agreement, alongside CLS milestone, royalty, and share-issuance obligations.
- The status and concentration of Takeda royalty revenue, the company’s principal reported revenue source.
- Nasdaq bid-price compliance and any reverse-split action, as well as potential dilution from preferred stock, warrants, options, and future equity issuance.
- Collection of the Pharmsynthez related-party loan: required payments were not fully made as of year-end, and the filing reports approximately $0.4 million as a long-term asset.